Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".

Suppr

超能文献

作者信息

Govindarajan Raghav, Salgado Efrain

出版信息

Circulation. 2012 Jan 24;125(3):e290; author reply e293-4. doi: 10.1161/CIRCULATIONAHA.111.053710.

DOI:10.1161/CIRCULATIONAHA.111.053710

PMID:22271856

Abstract

摘要

相似文献

Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".

Circulation. 2012 Jan 24;125(3):e290; author reply e293-4. doi: 10.1161/CIRCULATIONAHA.111.053710.

Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".

Circulation. 2012 Jan 24;125(3):e292; author reply e293-4. doi: 10.1161/CIRCULATIONAHA.111.057422.

Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".

Circulation. 2012 Jan 24;125(3):e291; author reply e293-4. doi: 10.1161/CIRCULATIONAHA.111.056077.

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16.

Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.

J Am Coll Cardiol. 2013 Sep 3;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042. Epub 2013 Jun 13.

Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.

Circulation. 2014 Mar 4;129(9):961-70. doi: 10.1161/CIRCULATIONAHA.113.003628. Epub 2013 Dec 9.

Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.

Nat Rev Nephrol. 2015 Jan;11(1):3. doi: 10.1038/nrneph.2014.221. Epub 2014 Nov 25.

Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.

Nat Rev Gastroenterol Hepatol. 2015 Mar;12(3):131-2. doi: 10.1038/nrgastro.2015.7. Epub 2015 Jan 20.

Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".

Circulation. 2013 Mar 19;127(11):e504. doi: 10.1161/CIRCULATIONAHA.112.133041.

Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".

Circulation. 2013 Mar 19;127(11):e505. doi: 10.1161/CIRCULATIONAHA.112.135343.

引用本文的文献

Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis.

Anatol J Cardiol. 2022 Jun;26(6):424-433. doi: 10.5152/AnatolJCardiol.2022.1376.

Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis.

Cardiol Res Pract. 2022 Mar 7;2022:4713826. doi: 10.1155/2022/4713826. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验